Business Description
Nanoviricides Inc
NAICS : 325412
SIC : 2834
ISIN : US6300873022
Total Employee Number:
7Description
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.9 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 3.4 | |||||
3-Year EPS without NRI Growth Rate | 3.5 | |||||
3-Year FCF Growth Rate | -1.6 | |||||
3-Year Book Growth Rate | -39 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 28.7 | |||||
9-Day RSI | 31.1 | |||||
14-Day RSI | 36.3 | |||||
3-1 Month Momentum % | -1.99 | |||||
6-1 Month Momentum % | 48 | |||||
12-1 Month Momentum % | 3.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.17 | |||||
Quick Ratio | 3.17 | |||||
Cash Ratio | 3.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.7 | |||||
Shareholder Yield % | -24.42 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -92.46 | |||||
ROA % | -81.4 | |||||
ROIC % | -115.15 | |||||
3-Year ROIIC % | 72.66 | |||||
ROC (Joel Greenblatt) % | -119.91 | |||||
ROCE % | -92.6 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.05 | |||||
Price-to-Tangible-Book | 3.12 | |||||
EV-to-EBIT | -3.64 | |||||
EV-to-EBITDA | -3.9 | |||||
EV-to-FCF | -4 | |||||
| Price-to-Net-Current-Asset-Value | 11.64 | |||||
| Price-to-Net-Cash | 12.8 | |||||
Earnings Yield (Greenblatt) % | -27.47 | |||||
FCF Yield % | -22.53 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with AMEX:NNVC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nanoviricides Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.43 | ||
| Beta | 2.323 | ||
| 3-Year Sharpe Ratio | 0.26 | ||
| 3-Year Sortino Ratio | 0.56 | ||
| Volatility % | 77.14 | ||
| 14-Day RSI | 36.3 | ||
| 14-Day ATR ($) | 0.0889 | ||
| 20-Day SMA ($) | 1.3895 | ||
| 12-1 Month Momentum % | 3.5 | ||
| 52-Week Range ($) | 0.85 - 2.2299 | ||
| Shares Outstanding (Mil) | 25.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nanoviricides Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nanoviricides Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2027-02-17 | In 174 days | ||
| General meeting for 2026 | 2026-11-06 10:00 | In 72 days | ||
| Annual report for 2026 | 2026-09-29 | In 33 days | ||
| Third quarter earnings results for 2026 | 2026-05-15 | 1.74 (+0.58%) | ||
| Second quarter earnings results for 2026 | 2026-02-17 | 1.00 (+7.53%) | ||
| General meeting for 2025 | 2025-11-08 10:00 | 1.84 (-0.54%) | ||
| Annual report for 2025 | 2025-09-29 | 1.42 (+1.43%) | ||
| Third quarter earnings results for 2025 | 2025-05-15 | 1.26 (+1.61%) | ||
| Second quarter earnings results for 2025 | 2025-02-14 | 1.29 (-7.86%) | ||
| General meeting for 2024 | 2024-12-07 10:00 | 1.50 (+2.04%) |
Show
Entries
Nanoviricides Inc Frequently Asked Questions
What is Nanoviricides Inc(NNVC)'s stock price today?
The current price of NNVC is $1.28. The 52 week high of NNVC is $2.23 and 52 week low is $0.85.
When is next earnings date of Nanoviricides Inc(NNVC)?
The next earnings date of Nanoviricides Inc(NNVC) is .
Does Nanoviricides Inc(NNVC) pay dividends? If so, how much?
Nanoviricides Inc(NNVC) does not pay dividend.
Press Release
Articles on Nanoviricides Inc
Nanoviricides (NNVC) Advances NV-387 Ebola Treatment Trial Amidst Mixed Financial Signals
Aug 18, 2026
Nanoviricides (NNVC) Gains Regulatory Approval for Ebola Trial Amid Mixed Valuation Signals
Aug 10, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers